ClinicalTrials.gg
RecruitingNCT07947472IMPOCNPICUpdated Nov 19, 2026

Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN)

An observational study in Chemotherapy-induced Peripheral Neuropathy, sponsored by Centre Hospitalier Intercommunal Creteil. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Centre Hospitalier Intercommunal Creteil · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,209 studies in Breast Neoplasms with a site in France — 208 open to participants now, 342 under way, 83 of them phase 3. Breast Neoplasms · France.

Planned enrollment
167th of 203
50 · median 200
Started
2026
with 43 others
Observational
204 of 1,209
44 open now
Primary completion
2027-02
later than 158 of 341 live
Registered
1,209th of 1,209
by date

Among the 1,209 studies in Breast Neoplasms with a site in France, this one is the 167th largest by planned enrollment of the 203 observational ones that give a count, is one of 44 that started in 2026, is one of 204 observational ones, reaches primary completion later than 158 of the 341 other live ones, and was the 1,209th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

208 of the 1,209 studies in Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

202 more — sign in →

All 208 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,209 studies in Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

Advances in cancer treatment have increased the number of patients living with long-term treatment-related consequences. Among these, chemotherapy-induced peripheral neuropathy (CIPN) is common and can significantly affect patients' quality of life and daily activities. Despite its impact, CIPN remains difficult to manage, and patients often receive insufficient support regarding its functional and occupational consequences.

Occupational therapy remains underutilised in oncology, despite its potential to help patients maintain or regain independence in meaningful daily activities. Collaboration between Advanced Practice Nurses and occupational therapists could improve the identification and management of occupational difficulties associated with CIPN.

The aim of this study is to describe the occupations affected by CIPN using the Canadian Occupational Performance Measure (COPM). The findings will help identify patients' occupational needs and guide future occupational therapy interventions.

Read the detailed description

In 2023, 433,136 new cancer cases were reported in France, accounting for 8.1 million hospital admissions. Thanks to advances in cancer treatment, the number of patients living with long-term consequences of cancer or its treatment is steadily increasing.

Cancer control policies in France have been based on successive Cancer Plans, followed by the adoption of the 2021-2030 Ten-Year Cancer Control Strategy. This strategy is structured around four priority areas, including the second: "Reducing long-term consequences and improving quality of life." Indeed, two out of three people experience lasting effects five years after a cancer diagnosis. This priority aims to promote research to reduce long-term consequences and improve patients' quality of life, as well as to prevent, detect and manage the effects associated with the disease and its treatments. In particular, findings from the VICAN 5 study show that 63.5% of cancer survivors continue to experience disease- or treatment-related consequences five years after diagnosis. Among these patients, 35.3% reported neuropathic pain, which negatively affects their quality of life and daily activities. Chemotherapy-induced peripheral neuropathy (CIPN) is common and remains difficult to manage because of its limited response to pharmacological treatments.

Current literature highlights a lack of support and care for patients experiencing CIPN, as well as insufficient knowledge regarding its impact on their daily activities and occupations.

The cancer care pathway can be divided into three main stages: diagnosis disclosure, treatment, and post-cancer care. Advanced Practice Nurses (APNs) can intervene at different stages of this pathway. They play a major role in long-term follow-up, particularly in identifying and monitoring treatment-related side effects and long-term consequences. However, their role, which primarily focuses on screening and monitoring, does not allow them to provide specific interventions aimed at improving the management of CIPN-related difficulties.

Occupational therapy aims to help individuals regain or maintain their independence in carrying out everyday activities. It offers a wide range of interventions but remains underutilised in oncology, for several reasons, including limited awareness of the profession, insufficient knowledge of its potential benefits, and difficulties accessing occupational therapy services.

In the management of CIPN, collaboration between Advanced Practice Nurses and occupational therapists could help establish effective care pathways, combine their respective expertise and promote patients' engagement in activities affected by CIPN.

The objective of this study is to describe the occupations (activities or groups of activities performed regularly and considered meaningful and valuable by individuals) affected by CIPN, using the Canadian Occupational Performance Measure (COPM).

Occupational performance is defined as an individual's ability to perform meaningful occupations adequately, efficiently and to their own satisfaction.

03

Conditions studied

  • Chemotherapy-induced Peripheral Neuropathy

Keywords

  • Canadian Occupational Performance Measure
  • Breast cancer
  • Colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with chemotherapy-induced peripheral neuropathy, grade 2 or 3 according to CTCAE: caused by paclitaxel in cases of breast cancer or by oxaliplatin in cases of colorectal cancer.

Patients must be able to carry on a conversation in French.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient treated for breast cancer or colorectal cancer, who has not previously received paclitaxel or oxaliplatin.
  • Patient with grade 2 or 3 peripheral neuropathy, according to the criteria, occurring during their treatment.
  • Patient able to communicate in French.
  • Patient aged 18 years or older

Exclusion criteria

Exclusion Criteria:

  • History of neuropathy prior to treatment.
  • Refusal to participate in the study.
  • Protected persons (pregnant or breastfeeding women, individuals under guardianship or curatorship, minors, individuals deprived of their liberty, or individuals unable to provide ).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Description of the occupational issues identified as priorities by patients

    Describe the occupational issues identified as priorities by patients based on the categories and subcategories of occupations defined by the MCRO

    Time frame: 3 months

Secondary outcomes

  1. Patient verbatim

    Patient verbatim statements regarding their priority occupational issues, grouped according to the MCRO categories and subcategories

    Time frame: 3 months

  2. Performance and satisfaction scores

    Performance and satisfaction scores obtained across each category and subcategory of the MCRO

    Time frame: 3 months

  3. Number and percentages of priority problematic occupations

    Number and percentages of priority problematic occupations, coded according to the categories and subcategories of the MCRO, based on the two types of treatment received.

    Time frame: 3 months

  4. Number and percentages of priority adverse events

    Number and percentages of priority adverse events, coded according to the categories and subcategories of the MCRO, based on the two CTCAE grading scales

    Time frame: 3 months

  5. Average time to onset of NPICs by treatment received

    Average time to onset of NPICs by treatment received. The time to onset of NPICs is defined as the interval (in days) between the start date of treatment and the date of NPIC diagnosis

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Feb 2027, 3 months after the start.

Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 3 months is below that.

Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartActual
Nov 9, 2026
Primary completionEst.
Feb 9, 2027
CompletionEst.
Feb 9, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947472
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 9, 2026
Primary completion
Feb 9, 2027 (estimated)
Completion
Feb 9, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Camille Jung
Contact
Camille.Jung@chicreteil.fr
01 57 02 22 68

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion